A small molecule, KAN0439834 (535 Da), targeting the TK domain of ROR1 was developed from a library of 110.000 compounds using fresh CLL cells (disease related cell phonotype selection procedure) specifically inhibiting phosphorylation of the TK domain (Supplementary Methods, Information and Figures). Here, TKT is linked to B-cell chronic lymphocytic leukemia.